The stock is listed on the Nasdaq Global Select Market

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a public offering by Revolution Medicines, Inc. of 16,304,353 shares of common stock at $46.00 per share and pre-funded warrants to purchase 2,173,917 shares of common stock at $45.9999 per pre-funded warrant, which included 2,445,652 shares of common stock from the full exercise of the underwriters’ option to purchase additional shares, for total gross proceeds of approximately $750 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “RVMD.”

Based in Redwood City, California, Revolution Medicines is a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.

The Davis Polk corporate team included partner Alan F. Denenberg and associate Elsie Cheang. Partner David R. Bauer and associate Adrian Rabin provided intellectual property advice. The tax team included partner Aliza Slansky and associates Alanna Phillips and Carter Ballentine Allison. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post